SEATTLE, Feb. 3 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that executives will present a corporate update and an overview of the company at two upcoming investor conferences in February and March:
-- Feb. 10: BIO CEO & Investor Conference at the Waldorf Astoria, 301 Park Ave., in New York City. Peter Thompson, M.D., FACP, president, CEO and chairman, is scheduled to present at 9 a.m. EST. A replay of the webcast will be available one hour after the presentation has ended at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TRBN&item_id=2079646.
-- March 18: Invest Northwest Investor Conference at the Bell Harbor International Convention Center, 2211 Alaskan Way, in Seattle. Michelle Burris, chief financial officer and senior vice president, is scheduled to present at 10:50 a.m. PST. A replay of the webcast will be available after the presentation at http://www.wsw.com/webcast/in7/trbn/.
Trubion is a biopharmaceutical company that is creating a pipeline of
novel protein therapeutic product candidates to treat autoimmune and
inflammatory diseases and cancer. The company's mission is to develop a
variety of first-in-class and best-in-class product candidates, customized for
optimal safety, efficacy and convenience that it believes may offer improved
patient experiences. Trubion's current product candidates are novel single-
chain protein, or SMIP(TM), therapeutics, and are designed using its custom
drug assembly technology. Trubion's product pipeline includes CD20-directed
SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and infl
|SOURCE Trubion Pharmaceuticals Inc.|
Copyright©2009 PR Newswire.
All rights reserved